Vítězslav Bryja

Laboratory of Cellular Communication

Head: Vitězslav Bryja
Brno node

bryja@sci.muni.cz
website of the Institute

HOME INSTITUTION

Faculty of Science MU

RESEARCH PROGRAMME(S)

RP 1 - Molecular basis of cancer and molecular targets
RP 3 - Biomarkers of cancers and cancer diagnostics

If you want to win, know your enemy first: From Molecular Principles to Therapeutic Innovations!

COLLABORATION WITH INFRASTRUCTURES

Mission: Our mission is to uncover the molecular principles controlling communication between the tumor cell and the surrounding tissue. We are dedicated to basic research on which we build the development of innovative chemotherapeutics. In parallel, we aim to use this knowledge to better diagnose cancer using biomarkers such as circulating tumor cells and extracellular vesicles.
Vision: Innovative cancer treatments and diagnostics that take advantage of the fact that cancer cells also need to interact with their environment to provide a supportive environment and energy resources. If we stop the communication that leads to the “enslavement” of the surrounding cells, we stop the development of the tumor.

Dysregulated intercellular communication is one of the most common reasons for tumor transformation. We use both proteomic and genomic (incl. single-cell RNASeq) approaches to understand the molecular mechanisms of cell communication, plasticity and diversity in tumors. We focus on the role of cellular heterogeneity and selected surface molecules in the diagnosis of cancer.

SELECTED PUBLICATIONS

Vyhlídalová Kotrbová A, et al., Proteomic analysis of ascitic extracellular vesicles describes tumour microenvironment and predicts patient survival in ovarian cancer. J Extracell Vesicles. 2024 Mar;13(3):e12420. DOI: 10.1002/jev2.12420
Němec V, et al., Discovery of Potent and Exquisitely Selective Inhibitors of Kinase CK1 with Tunable Isoform Selectivity. Angew Chem Int Ed Engl. 2023 Mar 6;62(11):e202217532. DOI: 10.1002/anie.202217532

Dani N, Herbst RH, McCabe C, Green GS, Kaiser K, Head JP, Cui J, Shipley FB, Jang A, Dionne D, Nguyen L, Rodman C, Riesenfeld SJ, Prochazka J, Prochazkova M, Sedlacek R, Zhang F, Bryja V, Rozenblatt-Rosen O, Habib N, Regev A, Lehtinen MK. A cellular and spatial map of the choroid plexus across brain ventricles and ages. Cell. 2021 May 27;184(11):3056-3074.e21. DOI: 10.1016/j.cell.2021.04.003
Radaszkiewicz T, Nosková M, Gömöryová K, Vondálová Blanářová O, Radaszkiewicz KA, Picková M, Víchová R, Gybeľ T, Kaiser K, Demková L, Kučerová L, Bárta T, Potěšil D, Zdráhal Z, Souček K, Bryja V. RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. Elife. 2021 Oct 27;10:e65759. DOI: 10.7554/eLife.65759
Kotrbová A, Ovesná P, Gybel’ T, Radaszkiewicz T, Bednaříková M, Hausnerová J, Jandáková E, Minář L, Crha I, Weinberger V, Záveský L, Bryja V, Pospíchalová V. WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer. Theranostics. 2020 Jan 1;10(2):537-552. DOI: 10.7150/thno.37423
Janovska P, Verner J, Kohoutek J, Bryjova L, Gregorova M, Dzimkova M, Skabrahova H, Radaszkiewicz T, Ovesna P, Vondalova Blanarova O, Nemcova T, Hoferova Z, Vasickova K, Smyckova L, Egle A, Pavlova S, Poppova L, Plevova K, Pospisilova S, Bryja V. Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218. DOI: 10.1182/blood-2017-05-786947